Tirzepatide vs Mounjaro vs Ozempic
Tirzepatide is the active pharmaceutical compound found in Mounjaro (diabetes) and Zepbound (obesity) — both manufactured by Eli Lilly. Ozempic and Wegovy contain semaglutide — a different compound. Understanding the difference is important for researchers:
- Semaglutide (Ozempic/Wegovy): GLP-1 receptor agonist only. Single mechanism.
- Tirzepatide (Mounjaro/Zepbound): GLP-1 + GIP dual agonist. Stronger effect than semaglutide.
- Retatrutide: GLP-1 + GIP + Glucagon triple agonist. Most potent in class.
NICE UK: Tirzepatide (Mounjaro) received NICE TA1026 approval for obesity management. NHS rollout began June 2025 for eligible patients with BMI ≥35. Research-grade tirzepatide from Jeo Peptides UK is for R&D use only.
Why Researchers Choose Tirzepatide
Phase 3 SURMOUNT trials showed average weight reduction of 20.9% at the 15mg dose. Tirzepatide is currently the most studied dual agonist compound globally — making it highly valuable for comparative and mechanistic research alongside retatrutide.
